Form 4: Entrada Therapeutics CFO Kory James Wentworth Sells Shares Under 10b5-1 Trading Plan

Kory James Wentworth, CFO of Entrada Therapeutics, sold 1,784 shares of common stock at $10.67 per share on March 17, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 17, 2025, Kory James Wentworth, the Chief Financial Officer of Entrada Therapeutics, Inc. (TRDA), sold 1,784 shares of the company's common stock.
• The sale was executed at a price of $10.67 per share.
• Following the transaction, Wentworth directly owns 109,536 shares of Entrada Therapeutics.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on March 15, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a negative outlook on the company.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of insider trading. The market typically views these sales in the context of the overall financial health and prospects of the company.

Stakeholder Impact

• The sale of shares by a company executive could potentially create uncertainty among shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Entrada Therapeutics, TRDA, Kory James Wentworth, CFO, Form 4, Share Sale, 10b5-1 Trading Plan, Insider Trading